About AMLo Biosciences
AMLo Biosciences is a company based in Newcastle Upon Tyne (United Kingdom) founded in 2017 by Penny Lovat and Marie Labus. It operates as a HealthTech. AMLo Biosciences has raised $7.69 million across 4 funding rounds from investors including Northstar Ventures, Esperante and Ascension. The company has 11 employees as of December 31, 2021. AMLo Biosciences offers products and services including AMBLor, cSCC Prognostic Test, and OPSCC Prognostic Test. AMLo Biosciences operates in a competitive market with competitors including DermTech, Castle Biosciences, Haut, MELAGENIX and Veriskin, among others.
- Headquarter Newcastle Upon Tyne, United Kingdom
- Employees 11 as on 31 Dec, 2021
- Founders Penny Lovat, Marie Labus
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Amlo Biosciences Limited
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$7.69 M (USD)
in 4 rounds
-
Latest Funding Round
$2.01 M (USD), Series A
Nov 27, 2024
-
Investors
Northstar Ventures
& 6 more
-
Employee Count
11
as on Dec 31, 2021
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of AMLo Biosciences
AMLo Biosciences offers a comprehensive portfolio of products and services, including AMBLor, cSCC Prognostic Test, and OPSCC Prognostic Test. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
AMBLor is developed for melanoma risk stratification purposes.
Test is designed for cutaneous squamous cell carcinoma prognosis.
Test is created for oropharyngeal squamous cell carcinoma prognosis.
Unlock access to complete
Unlock access to complete
Funding Insights of AMLo Biosciences
AMLo Biosciences has successfully raised a total of $7.69M across 4 strategic funding rounds. The most recent funding activity was a Series A round of $2.01 million completed in November 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 4
- Last Round Series A — $2.0M
-
First Round
First Round
(11 Oct 2018)
- Investors Count 7
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov, 2024 | Amount | Series A - AMLo Biosciences | Valuation | Northstar Ventures , Esperante |
|
| Apr, 2022 | Amount | Series A - AMLo Biosciences | Valuation |
investors |
|
| Nov, 2020 | Amount | Series A - AMLo Biosciences | Valuation | North East Fund , Milltrust International Group |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in AMLo Biosciences
AMLo Biosciences has secured backing from 7 investors, including venture fund investors. Prominent investors backing the company include Northstar Ventures, Esperante and Ascension. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Early-stage investments are made in UK companies across diverse sectors.
|
Founded Year | Domain | Location | |
|
Esperante is focused on innovative life science investments.
|
Founded Year | Domain | Location | |
|
Ascension is recognized as a venture capital firm focused on early-stage tech investments.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by AMLo Biosciences
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - AMLo Biosciences
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Amlo Biosciences Comparisons
Competitors of AMLo Biosciences
AMLo Biosciences operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as DermTech, Castle Biosciences, Haut, MELAGENIX and Veriskin, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Adhesive patch biopsies for skin cancer detection are provided.
|
|
| domain | founded_year | HQ Location |
Precision diagnostic and prognostic tests are developed by Castle Biosciences.
|
|
| domain | founded_year | HQ Location |
SaaS solutions using AI for skincare businesses are provided.
|
|
| domain | founded_year | HQ Location |
Molecular diagnostic tests for skin cancer detection are developed.
|
|
| domain | founded_year | HQ Location |
Tools for non-invasive skin cancer diagnosis are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Amlo Biosciences
Frequently Asked Questions about AMLo Biosciences
When was AMLo Biosciences founded?
AMLo Biosciences was founded in 2017 and raised its 1st funding round 1 year after it was founded.
Where is AMLo Biosciences located?
AMLo Biosciences is headquartered in Newcastle Upon Tyne, United Kingdom.
Who is the current CEO of AMLo Biosciences?
Marie Labus is the current CEO of AMLo Biosciences. They have also founded this company.
Is AMLo Biosciences a funded company?
AMLo Biosciences is a funded company, having raised a total of $7.69M across 4 funding rounds to date. The company's 1st funding round was a Series A of $1.99M, raised on Oct 11, 2018.
How many employees does AMLo Biosciences have?
As of Dec 31, 2021, the latest employee count at AMLo Biosciences is 11.
What does AMLo Biosciences do?
AMLo Biosciences is engaged in translating cancer biomarker research into prognostic and diagnostic products. The company targets melanoma, cutaneous squamous cell carcinoma, and oropharyngeal squamous cell carcinoma. Solutions are developed to improve patient outcomes by identifying disease progression risks. Efforts are directed towards reducing financial burdens on global healthcare systems. Products like AMBLor are designed to stratify risk in early-stage melanoma patients. The focus is maintained on optimizing healthcare resources through precise patient management.
Who are the top competitors of AMLo Biosciences?
AMLo Biosciences's top competitors include DermTech, Castle Biosciences and MELAGENIX.
What products or services does AMLo Biosciences offer?
AMLo Biosciences offers AMBLor, cSCC Prognostic Test, and OPSCC Prognostic Test.
Who are AMLo Biosciences's investors?
AMLo Biosciences has 7 investors. Key investors include Northstar Ventures, Esperante, Ascension, Conduit Connect, and Future Planet Capital.